High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation.
autoimmune hepatitis
azathioprine
cohort study
immunosupression
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
06
03
2020
revised:
20
04
2020
accepted:
07
05
2020
pubmed:
16
5
2020
medline:
22
6
2021
entrez:
16
5
2020
Statut:
ppublish
Résumé
Guidelines regarding treatment for autoimmune hepatitis (AIH) favour two strategies for azathioprine (AZA) introduction: concurrent with steroids at induction or delayed by 2-4 weeks. The safety and efficacy of both strategies have been unexplored. We established a cohort of 900 AIH patients from 12 centres in 7 European countries. There were 631 patients who used AZA as part of the therapeutic regimen. We distinguished two groups: patients with early AZA (<2 weeks) or delayed AZA initiation (≥2 weeks). Primary outcome was discontinuation of AZA in the first year of treatment. Cox regression and propensity score matching was performed to determine difference in outcomes between groups. Patients with early AZA initiation had significantly lower transaminases and bilirubin at baseline. Discontinuation rates of AZA did not differ between early and delayed starters (16.6% vs 14.2%), which did not reach statistical significance (hazard ratio 0.97, 95% confidence interval 0.61-1.55, P = .90). Stratification according to baseline disease activity or propensity score matching did not alter the results. Main reason for AZA discontinuation was intolerance to treatment (14.0% vs 13.2%, P = .78) with nausea and vomiting as main side effects. AIH remission rates were comparable among groups. The discontinuation rate of AZA in AIH treatment is ~15% in the first year of treatment. Early or delayed AZA initiation does not differ in remission and discontinuation rates in AIH induction therapy. Our data suggest that either strategy may be used as part of AIH treatment.
Sections du résumé
BACKGROUND
Guidelines regarding treatment for autoimmune hepatitis (AIH) favour two strategies for azathioprine (AZA) introduction: concurrent with steroids at induction or delayed by 2-4 weeks. The safety and efficacy of both strategies have been unexplored.
METHODS
We established a cohort of 900 AIH patients from 12 centres in 7 European countries. There were 631 patients who used AZA as part of the therapeutic regimen. We distinguished two groups: patients with early AZA (<2 weeks) or delayed AZA initiation (≥2 weeks). Primary outcome was discontinuation of AZA in the first year of treatment. Cox regression and propensity score matching was performed to determine difference in outcomes between groups.
RESULTS
Patients with early AZA initiation had significantly lower transaminases and bilirubin at baseline. Discontinuation rates of AZA did not differ between early and delayed starters (16.6% vs 14.2%), which did not reach statistical significance (hazard ratio 0.97, 95% confidence interval 0.61-1.55, P = .90). Stratification according to baseline disease activity or propensity score matching did not alter the results. Main reason for AZA discontinuation was intolerance to treatment (14.0% vs 13.2%, P = .78) with nausea and vomiting as main side effects. AIH remission rates were comparable among groups.
CONCLUSION
The discontinuation rate of AZA in AIH treatment is ~15% in the first year of treatment. Early or delayed AZA initiation does not differ in remission and discontinuation rates in AIH induction therapy. Our data suggest that either strategy may be used as part of AIH treatment.
Identifiants
pubmed: 32410363
doi: 10.1111/liv.14513
pmc: PMC7496382
doi:
Substances chimiques
Immunosuppressive Agents
0
Azathioprine
MRK240IY2L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2164-2171Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Hepatology. 1988 Jul-Aug;8(4):781-4
pubmed: 3292363
J Hepatol. 2014 Oct;61(4):876-82
pubmed: 24842305
Ann Rheum Dis. 1988 Jun;47(6):503-5
pubmed: 3382271
J Hepatol. 2015 Oct;63(4):971-1004
pubmed: 26341719
Hepatology. 2012 Feb;55(2):522-9
pubmed: 21994151
Lancet. 1964 Apr 25;1(7339):899-902
pubmed: 14124080
Eur J Gastroenterol Hepatol. 2004 Nov;16(12):1407-13
pubmed: 15618853
J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):391-8
pubmed: 12352536
Z Gastroenterol. 2001 May;39(5):339-41, 344-8
pubmed: 11413913
N Engl J Med. 1995 Oct 12;333(15):958-63
pubmed: 7666914
J Hepatol. 2011 Jul;55(1):171-82
pubmed: 21167232
Gut. 1975 Nov;16(11):876-83
pubmed: 1104411
Lancet. 1985 Mar 23;1(8430):668-70
pubmed: 2858619
Hepatology. 2010 Jun;51(6):2193-213
pubmed: 20513004
Liver Int. 2020 Sep;40(9):2164-2171
pubmed: 32410363
Am J Gastroenterol. 2005 May;100(5):1121-5
pubmed: 15842588
United European Gastroenterol J. 2019 Nov;7(9):1156-1163
pubmed: 31700628
Mayo Clin Proc. 1997 Jul;72(7):643-5
pubmed: 9212766
Hepatology. 2012 Oct;56(4):1401-8
pubmed: 22488741
Ital J Gastroenterol. 1996 Feb-Mar;28(2):102-4
pubmed: 8782004
J Hepatol. 2010 Jul;53(1):191-8
pubmed: 20400196
Scand J Gastroenterol. 2014 Oct;49(10):1245-54
pubmed: 25123213
Hepatology. 2008 Jul;48(1):169-76
pubmed: 18537184